How to buy Lava Therapeutics B-V (LVTX) stock

Lava Therapeutics B.V is a biotechnology business based in the US. Lava Therapeutics B-V shares (LVTX) are listed on the NASDAQ and all prices are listed in US Dollars. Lava Therapeutics B-V employs 28 staff and has a trailing 12-month revenue of around 0.00.

Lava Therapeutics B-V stock price (NASDAQ: LVTX)

Use our graph to track the performance of LVTX stocks over time.

Lava Therapeutics B-V shares at a glance

• Key figures

Information last updated 2021-07-23.

52-week range	$7.45 - $17.20
50-day moving average	$10.71
200-day moving average	$12.06
Wall St. target price	$23.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Lava Therapeutics B-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lava Therapeutics B-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lava Therapeutics B.V by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lava Therapeutics B-V financials

Revenue TTM	$4.1 million
Gross profit TTM	$-10,453,000
Return on assets TTM	-65.22%
Return on equity TTM	-237.94%
Profit margin	0%
Book value	$4.52
Market capitalisation	$198.4 million

TTM: trailing 12 months

Shorting Lava Therapeutics B-V shares

There are currently 140,164 Lava Therapeutics B-V shares held short by investors – that's known as Lava Therapeutics B-V's "short interest". This figure is 4.5% up from 134,072 last month.

There are a few different ways that this level of interest in shorting Lava Therapeutics B-V shares can be evaluated.

Lava Therapeutics B-V's "short interest ratio" (SIR)

Lava Therapeutics B-V's "short interest ratio" (SIR) is the quantity of Lava Therapeutics B-V shares currently shorted divided by the average quantity of Lava Therapeutics B-V shares traded daily (recently around 13185.70084666). Lava Therapeutics B-V's SIR currently stands at 10.63. In other words for every 100,000 Lava Therapeutics B-V shares traded daily on the market, roughly 10630 shares are currently held short.

To gain some more context, you can compare Lava Therapeutics B-V's short interest ratio against those of similar companies.

• MacroGenics (MGNX.US): 3.56
• Nektar Therapeutics (NKTR.US): 17.65
• Agios Pharmaceuticals (AGIO.US): 4.94

However Lava Therapeutics B-V's short interest can also be evaluated against the total number of Lava Therapeutics B-V shares, or, against the total number of tradable Lava Therapeutics B-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lava Therapeutics B-V's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Lava Therapeutics B-V shares in existence, roughly 10 shares are currently held short) or 0.0203% of the tradable shares (for every 100,000 tradable Lava Therapeutics B-V shares, roughly 20 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Lava Therapeutics B-V.

Find out more about how you can short Lava Therapeutics B-V stock.

Lava Therapeutics B-V share dividends

We're not expecting Lava Therapeutics B-V to pay a dividend over the next 12 months.

Lava Therapeutics B-V overview

Lava Therapeutics B. V. , a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B. V.

Frequently asked questions

What percentage of Lava Therapeutics B-V is owned by insiders or institutions?
Currently 32.39% of Lava Therapeutics B-V shares are held by insiders and 65.938% by institutions. How many people work for Lava Therapeutics B-V?
Latest data suggests 28 work at Lava Therapeutics B-V. When does the fiscal year end for Lava Therapeutics B-V?
Lava Therapeutics B-V's fiscal year ends in December. Where is Lava Therapeutics B-V based?
Lava Therapeutics B-V's address is: Yalelaan 60, Utrecht, Netherlands, 3584 CM